Evaluating SGLT2 inhibitors for type 2 diabetes: pharmacokinetic and toxicological considerations

ISSN： 1742-5255

Source： Expert Opinion on Drug Metabolism and Toxicology, Vol.10, Iss.5, 2014-05, pp. : 647-663

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

GLP-1 agonists for type 2 diabetes: pharmacokinetic and toxicological considerations

By Jespersen Maria J Knop Filip K Christensen Mikkel

Expert Opinion on Drug Metabolism and Toxicology, Vol. 9, Iss. 1, 2013-01 ,pp. : 17-29

Informa Healthcare

Access to resources Recommend Favorite

Design of SGLT2 Inhibitors for the Treatment of Type 2 Diabetes: A History Driven by Biology to Chemistry

Medicinal Chemistry, Vol. 11, Iss. 4, 2015-06 ,pp. : 317-328

Bentham Science Publishers

Access to resources Recommend Favorite

SGLT2: a potential target for the pharmacogenetics of Type 2 diabetes?

By Tönjes Anke Kovacs Peter

Pharmacogenomics, Vol. 14, Iss. 7, 2013-05 ,pp. : 825-833

Future Medicine

Access to resources Recommend Favorite

Linagliptin for the treatment of type 2 diabetes (pharmacokinetic evaluation)

By Scheen André J

Expert Opinion on Drug Metabolism and Toxicology, Vol. 7, Iss. 12, 2011-12 ,pp. : 1561-1576

Informa Healthcare

Access to resources Recommend Favorite

Pharmacokinetic and toxicological considerations for the treatment of diabetes in patients with liver disease

By Scheen André J

Expert Opinion on Drug Metabolism and Toxicology, Vol. 10, Iss. 6, 2014-06 ,pp. : 839-857

Informa Healthcare

Access to resources Recommend Favorite